SIGNIFICANCE OF miR-885-5p IN NEUROBLASTOMA OUTCOME
DOI: http://dx.doi.org/10.30970/sbi.0903.450
Abstract
Neuroblastoma is the most common extracranial malignant solid tumor in children. This disease displays a remarkable heterogeneity in clinical behavior, ranging from spontaneous regression to rapid progression and resistance to therapy. Recent evidence has shown that microRNAs are often involved in regulation of tumor development and progression. MiR-885-5p has a tumor suppressive role in neuroblastoma, interfering with cell cycle progression and cell survival. MiR-885-5p leads to the accumulation of p53 protein and activates p53-mediated pathway of cell cycle arrest, resulting in upregulation of its targets. We have analyzed association of miR-885-5p expression in 58 neuroblastoma tumors with different clinical characteristics and disease outcome. In tumor samples of patients with unfavorable clinical characteristics lower miR-885-5p expression levels were observed. Event-free survival analysis showed that low miR-885-5p expression was tightly associated with a significantly poorer outcome than in those with high expression of miR-885-5p. In this study, evidence is presented on miR-885-5p dysregulation in neuroblastoma. As follows, along with other clinical features, it can be used as an independent prognostic and possibly therapeutic approach for optimization of neuroblastoma treatment.
Keywords
Full Text:
PDFReferences
1. Afanasyeva E.A., Hotz-Wagenblatt A., Glatting K.H. et al. New miRNAs cloned from neuroblastoma. BMC Genomics, 2008; 9(52): 1-17. | |
| |
2. Afanasyeva E.A., Mestdagh P., Kumps C. et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death and Differentiation, 2011; 18(6): 974-984. | |
| |
3. Bollati V., Baccarelli A. Environmental epigenetics. Heredity, 2010; 105(1): 105-112. | |
| |
4. Brodeur G.M. Seeger R.C., Schwab M. et al. Amplification of n-Myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 1984; 224(4653): 1121-1124. | |
| |
5. Capasso M., Diskin S. Genetics and genomics of neuroblastoma. Pasche B. (Ed.) Cancer Genetics, Cancer Treatment and Research. Springer Science LLC, 2010: 65-84. | |
| |
6. Evans A.E., D'Angio G.J. Age at Diagnosis and Prognosis in Children With Neuroblastoma. Journal of Clinical Oncology, 2005; 23(27): 6443-6444. | |
| |
7. Gurney J.G., Severson R.K., Davis S. et al. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer, 1995; 75(8): 2186-2195. | |
| |
8. Inomistova M.V., Svergun N.M., Khranovska N.M. et al. Prognostic significance of MDM2 gene expression in childhood neuroblastoma. Experimental Oncology, 2015; 37(2): 111-115. | |
| |
9. Khranovska N.M., Inomistova M.V., Svergun N.M. et al. The role of alteration of p53/MDM2 pathway regulation in neuroblastoma progression. Clinical Oncology, 2014; 4(16): 18-21. (In Ukrainian) | |
| |
10. Khranovska N.M., Inomistova M.V., Klymnyuk G.I. Role of miRNAs in neuroblastoma pathogenesis (review). Clinical Oncology, 2013; 1(9): 145-148. | |
| |
11. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993; 75(5): 843-854. | |
| |
12. Lu J., Getz G., Miska E.A. et al. MicroRNA expression profiles classify human cancers. Nature, 2005; 435(7043): 834-838. | |
| |
13. Tweddle, D.A. Pearson A.D., Haber M. et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett, 2003; 197: 93-98. | |
| |
14. Tweddle D.A., Malcolm A.J., Bown N. et al. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Research, 2001; 61: 8-13. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2015 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.